DNA vaccines against cancer come of age

Genetic technology allows construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways. Their enormous promise has been marred by a problem of scaling up to human subjects. This is now largely overcome by electroporation, w...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in immunology Vol. 22; no. 2; pp. 264 - 270
Main Authors Stevenson, Freda K, Ottensmeier, Christian H, Rice, Jason
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2010
Subjects
Allergy and Immunology
Animals
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Cancer Vaccines
Clinical Trials as Topic
DNA - immunology
Electroporation
Humans
Immunity
Mice
Receptors, Pattern Recognition - immunology
Recombinant Fusion Proteins - genetics
Recombinant Fusion Proteins - immunology
Vaccines, DNA - genetics
Vaccines, DNA - immunology
Online AccessGet full text

Cover

More Information
Summary:Genetic technology allows construction of DNA vaccines encoding selected tumor antigens together with molecules to direct and amplify the desired effector pathways. Their enormous promise has been marred by a problem of scaling up to human subjects. This is now largely overcome by electroporation, which increases both antigen expression and the inflammatory milieu. While the principles of vaccine design can be developed in mouse models, the real operative test is in the clinic, using patients in temporary remission. Monitoring of induced immunity, although commonly limited to blood, is providing objective qualitative and quantitative data on T-cell and antibody responses. Prolongation of remission is the goal and an activated immune system should achieve this.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0952-7915
1879-0372
1879-0372
DOI:10.1016/j.coi.2010.01.019